biostudies-literatureUnknown6(8)Liu HMerck &amp; Co IncPfizer Canada Inc<h4>Introduction</h4>Sodium-glucose cotransporter-2 (SGLT2) inhibitors improve cardiovascular and kidney outcomes through mechanisms that are incompletely understood. In this exploratory post-hoc analysis of the VERTIS RENAL trial, we report the association between the SGLT2 inhibitor, ertugliflozin, and markers of kidney injury, inflammation, and fibrosis in participants with type 2 diabetes (T2D) and stage 3 chronic kidney disease (CKD).<h4>Methods</h4>Participants were randomized to ertugliflozin (5 or 15 mg/d) or placebo, and plasma samples for biomarker analysis were collected at baseline, 26 weeks, and 52 weeks.<h4>Results</h4>Ertugliflozin-treated participants had lower plasma levels of kidney injury molecule-1 (KIM-1) at 26 weeks (<i>P</i> = 0.044) and 52 weeks (<i>P</i> = 0.007) aKidney international reports2095-2104https://www.ebi.ac.uk/biostudies/studies/S-EPMC8343791biostudies-literatureMarkers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes.PMC8343791Liu HBurger DBurns KCherney DZISridhar VSLytvyn YBrinc DLawler PRLovblom LEfalseMarkers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes.<h4>Introduction</h4>Sodium-glucose cotransporter-2 (SGLT2) inhibitors improve cardiovascular and kidney outcomes through mechanisms that are incompletely understood. In this exploratory post-hoc analysis of the VERTIS RENAL trial, we report the association between the SGLT2 inhibitor, ertugliflozin, and markers of kidney injury, inflammation, and fibrosis in participants with type 2 diabetes (T2D) and stage 3 chronic kidney disease (CKD).<h4>Methods</h4>Participants were randomized to ertugliflozin (5 or 15 mg/d) or placebo, and plasma samples for biomarker analysis were collected at baseline, 26 weeks, and 52 weeks.<h4>Results</h4>Ertugliflozin-treated participants had lower plasma levels of kidney injury molecule-1 (KIM-1) at 26 weeks (<i>P</i> = 0.044) and 52 weeks (<i>P</i> = 0.007) a2021-01-01T00:00:00Z2021 Aug2026-05-08T20:56:10.935Z2022-02-11T07:26:43.128ZS-EPMC83437913438665810.1016/j.ekir.2021.05.022